HomeUSACurie.Bio Raises $380M Pro Rata Series A Fund

Curie.Bio Raises $380M Pro Rata Series A Fund


Curie.Bio, a Cambridge, Mass.-based seed-stage venture firm combined with an industry-grade therapeutics accelerator, closed its latest fund, at $380m.

These funds will enable the firm to continue investing in early-stage therapeutics companies on their path to generating clinical data. The majority of this capital will be directed towards Series A rounds for clinical proof-of-concept studies, demonstrating clinical benefits for patients.

The firm invests in platform and asset-centric companies, and in either case, each of the company’s programs must have blockbuster potential ($1B peak sales) on their own.

Curie.Bio leverages a VC model that aims to improve the ability to create medicines while minimizing long-term dilution. The 50-person team and a capital-efficient model provide founders with access to the industry’s top drug hunters, operators, and R&D services from day one.

The co-pilots help founders define and execute the best possible seed work plan. This group has made significant contributions to 150+ clinical-stage drugs and 30+ registered products. They also help people choose the best therapeutic targets and the right TPPs to enable efficacy in the optimal indications.

Its portfolio of 20 early-stage therapeutics companies includes a wide diversity of founder backgrounds, therapeutic areas, drug modalities, and geographies.

This brought the total funds raised by Curie.Bio to nearly $1 billion.